62 results about "Lung tumours" patented technology

The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.

The present invention provides molecules that selectively home to various normal organs or tissues, including to lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut; and provides molecules that selectively home to tumor bearing organs or tissues, including to pancreas bearing a pancreatic tumor or to lung bearing a lung tumor. The invention also provides conjugates, comprising an organ or tissue homing molecule linked to a moiety. Such a moiety can be, for example, a therapeutic agent or a detectable agent. In addition, the invention provides methods of using an organ homing molecule of the invention to identify a particular organ or tissue by contacting the organ or tissue with a molecule of the invention. The invention also provides methods to diagnose or treat a pathology of the lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut by administering to a subject having or suspected of having a pathology a molecule that homes to the selected organ or tissue. The invention further provides methods of identifying a target molecule in lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut.

The present invention provides molecules that selectively home to various normal organs or tissues, including to lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut; and provides molecules that selectively home to tumor bearing organs or tissues, including to pancreas bearing a pancreatic tumor or to lung bearing a lung tumor. The invention also provides conjugates, comprising an organ or tissue homing molecule linked to a moiety. Such a moiety can be, for example, a therapeutic agent or a detectable agent. In addition, the invention provides methods of using an organ homing molecule of the invention to identify a particular organ or tissue by contacting the organ or tissue with a molecule of the invention. The invention also provides methods to diagnose or treat a pathology of the lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut by administering to a subject having or suspected of having a pathology a molecule that homes to the selected organ or tissue. The invention further provides methods of identifying a target molecule in lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut.

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and / or treatment of diseases, particularly lung cancer.

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and / or treatment of diseases, particularly lung cancer.

The invention discloses a method for constructing a benign and malignant lung tumor prediction model. The method comprises the following steps that (1) a lung tumor patient sample is selected and computerized tomography (CT) is performed on the lung region of the lung tumor patient so as to acquire the corresponding CT image; (2) the CT image acquired in the step (1) is sketched and the lung lesion region is segmented so as to obtain the marked lesion region; (3) quantitative image features are extracted from the marked lesion region; (4) feature selection is performed by using the Lasso algorithm; and (5) the selected feature data act as the input, parameter optimization is performed on Logistic regression by using the gradient descent algorithm and finally the benign and malignant lung tumor prediction model is obtained by using Logistic training. The method for constructing the benign and malignant lung tumor prediction model is simple, short in time consumption and high in accuracyof the prediction model and can be applied to qualitative diagnosis of the benign and malignant lung tumors.

The invention discloses an automatic lung tumour segmentation method based on a random forest and a monotonically decreasing function. The automatic lung tumour segmentation method comprises the following steps: obtaining the initial position of a lung tumour by utilizing the brightness variation characteristic of the tumour on a PET image, then, sufficiently utilizing metabolic information of the tumour on the PET image and anatomic information of the tumour on a CT image through characteristic extraction, and finally, realizing precision segmentation of the tumour through a random forests algorithm. The automatic lung tumour segmentation method based on the random forest and the monotonically decreasing function provided by the invention is capable of determining the position and the size of the lung tumour automatically and precisely; therefore, a doctor can be clinically assisted to treat the lung tumour; and more rapid and more precise full-automatic lung tumour segmentation can be realized without artificial intervention.

The present invention relates to a method for performing computer-aided detection (CAD) of a disease, e.g. lung tumours, on a medical image data set (20) from a imaging modality, such as MRI or CT. Initially, there is perform a segmentation of the medical image data set (20) using an anatomical model. Secondly, the segmented data is analyzed for characteristics of the disease resulting in a set of analysis data (25), and finally the set of analysis data (25) is evaluating with respect to the disease. At least one of these steps comprises as an input a position dependent probability (P_r) for the disease. The invention is advantageous in that more efficient computations can be performed because the degree of analysis in a certain region of the part of the patient, e.g. the lung, can be adjusted or tailored to the level of probability of the disease in the that region. It is thereby possible to increase computational speed and thereby diseases like cancer, in particular cancer nodules in the lungs, can be more effectively found from medical image analysis.

Provided are methods of treating lung cancer in a patient in need thereof. The method includes administration to the patient a composition comprising a therapeutically effective amount of a compound that reduces the expression level of E3 ubiquitin-protein ligase MDM2. The compound in certain instances is a miR-660 miRNA, or a functional variant thereof. The patient in need of treatment in certain instances expresses miR-660 in a lung tissue sample or biological fluid sample at a level lower as compared to a control level derived from a subject or plurality of subjects that do not have lung cancer, or as compared to a control level derived from a lung cancer patient or plurality thereof, that have been given a favorable prognosis; expresses MDM2 at a higher level in a lung tissue sample or biological fluid sample as compared to a control level derived from a subject or plurality of subjects that do not have lung cancer, or as compared to a control level derived from a lung cancer patient or plurality thereof that have been given a favorable prognosis; and / or expresses p53 in a lung tissue sample or a biological fluid sample below a control level derived from a lung tumor tissue sample, or plurality thereof, or a biological fluid sample, or plurality thereof, obtained from a patient that has a favorable lung cancer prognosis; or a control level derived from a healthy subject.

Compounds and methods for treating lung cancer are disclosed. The inventive compounds include polypeptides containing at least a portion of a lung tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of lung cancer comprising such polypeptides, or polynucleotides encoding such polypeptides, are also disclosed, together with polynucleotides for preparing the inventive polypeptides.

Compositions and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compositions comprise one or more polynucleotides that encode a lung tumor protein, or a fragment or variant thereof. The compositions may be used to detect an mRNA encoding a lung tumor protein in a sample.

Diagnosis of lung cancer in a subject before onset of symptoms is described herein (i.e., in a pre-diagnostic subject), by screening a biological fluid from the subject for the presence therein of autoantibodies that are specific for one or more pre-diagnostic lung cancer indicator proteins, including LAMR1, and optionally additionally or alternatively including annexin I and / or 14-3-3-theta and / or other pre-diagnostic lung cancer indicator proteins as presently disclosed, as the defined antigens. Related methods, including for monitoring immune reactivity against lung cancer indicator proteins in a lung cancer patient, typing lung cancer subjects or characterizing lung tumors, and application of the described proteomics approach for the identification of additional pre-diagnostic lung cancer indicator proteins, are also contemplated.

A lung tumor ablation planning system includes a processor operable to compute a target ablation zone and a set of optimum ablation parameters to create the target lesion with the ablation catheter. Apredictive algorithm is employed to model the ablation zone based on training data. Various ablation plans are displayed to the physician corresponding to various metrics including without limitationmaximizing tumor ablation coverage, shortest travel, obstacle avoidance, and shortest ablation time. Related methods are described.

The method is suitable for the technical field of medical image processing. The invention provides a lung tumor automatic sketching method based on deep learning, and the method comprises the steps: obtaining an input lung CT image when a sketching request of the lung CT image is received, carrying out the preprocessing and image enhancement of the obtained lung CT image, and obtaining a corresponding processed image; obtaining the position and size of a window of the lung tumor in the image, and cutting the screened image into a fixed size; inputting the processed image into a trained V-Net model so as to predict the lung tumor; performing deconvolution on the predicted tumor image to the size of the cut image, so that real prediction of the tumor can be obtained; and extracting the edgeline of the truly predicted lung tumor, that is, sketching the lung tumor, and obtaining an image sketched by the lung tumor. According to the lung tumor automatic sketching device, the accuracy of automatic sketching of lung tumors is improved, the sketching efficiency is remarkably improved on the basis of guaranteeing the sketching precision, and the operation safety process is improved.

Devices and methods for melting lung tumors, and specifically a method of melting a lung tumor in the respiratory tract of a patient are disclosed.

According to the composite drug-loaded extracellular vesicle inhalation preparation and the preparation method and application thereof, the extracellular vesicle inhalation preparation is used for treating lung tumors in an oral inhalation administration mode, the residence time of treatment drugs in a body can be effectively prolonged, distribution of the drugs in other non-target tissues and organs in the body is reduced. The toxic and side effects of the medicine are reduced while the treatment effect is enhanced, and the medicine shows a good treatment effect of remarkably inhibiting the growth of drug-resistant lung tumors in an animal model.

Methods are provided for identifying whether a lung tumor will be responsive to treatment with the combination of the therapeutic agents cisplatin and pemetrexed. Specified ERCC1, TS, p16, and FRα fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in lung tumor cells collected from lung tumor tissue that was obtained from a cancer patient and compared to reference levels in order to determine if the lung cancer patient will positively respond to treatment with the combination of cisplatin and pemetrexed therapeutic agents.

The present invention provides a method of determining the presence of a pulmonary tumor in a subject is provided. Also provided is a method of determining the presence of an aggressive pulmonary tumor in a subject. Additionally, a method of determining the risk of manifesting a pulmonary tumor in a subject is provided. Further provided is a method of determining the risk of manifesting an aggressive pulmonary tumor in a subject. A method for predicting the risk of developing or having a pulmonary tumor in a subject is also provided. A method of establishing lung cancer treatment options is additionally provided.

The invention relates to the technical field of image processing, and specifically relates to a lung malignant tumor MRI identification method utilizing a maximum class separation distance method of a genetic algorithm. For the lung malignant tumor MRI identification method, a non-linear genetic array optimization model is added, and optimization of segmented images can be performed through the non-linear genetic array optimization model. Therefore, the segmented images obtained through the method are high in accuracy so that the identification of lung tumour is higher in accuracy.

The invention belongs to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating lung malignant tumor and an usage thereof. The traditional Chinese medicine composition comprises powder and preparation. The effective components of the powder include seaweed, semen cassiae , kelp, 10 to 20 radix angelicae dahuricae, fritillaria cirrhosa, alpinia oxyphylla, rhizoma cyperi, poria cocos, radix platycodi, fructus psoraleae and bighead atractylodes rhizome. The effective components of the preparation include clematis chinensis, angelica sinensis, prepared rhizome of rehmannia, oroxylum indicum, radix codonopsis, ligusticum wallichii, glossy privet fruit, astragalus, the root of red-rooted salvia and achyranthis bidentatae. The traditional Chinese medicine composition has the advantages that the powder and preparation are used interchangeably and drug properties are complementary to each other, and has the effects of benefiting qi and resolving blood stasis, clearing heat and removing toxicity, nourishing yin and moisturizing lung and relieving cough and reducing sputum, can inhibit the growth of tumor cells while improving the immune resistance of the organism, and has a good healing effect on lung tumor, especially for early-stage cancer and the cure rate is more than 95%. Taking the traditional Chinese medicine composition has the advantages of quick effect, short treatment course, low cost, and has no side effect.

The present invention discloses a targeting polypeptide-fluorescent magnetic nanometer complex, a preparation method and applications thereof. According to the present invention, magnetic nanoparticles are adopted as the base, a fluorescent molecule is adopted as a display material, and the polypeptide of stem cells capable of targeting lung cancers is modified to construct the targeting polypeptide-fluorescent magnetic nanometer complex; and the targeting polypeptide-fluorescent magnetic nanometer complex has characteristics of fluorescent tracing capability, magnetic resonance developing capability and specific targeting capability, can efficiently and precisely identify, label, sort and enrich lung tumor stem cells, especially H460 lung tumor stem cells, can be used for monitoring of lung cancer metastasis and treatment effects, provides basis and assurance for lung cancer treatment, substantially reduce the suffering and the economic burden of patients, improve the life quality of patients, is easy to prepare, and has low cost.

The invention discloses a functional drug-loaded system used for treating lung tumour and a preparation method and an application thereof. The drug-loaded system is drug-loaded liposome, which is obtained through entrapment of a medicine by the targeting liposome, and the targeting liposome is prepared by phosphatidylcholine bilayer, cholesterol, distearoyl phosphoethanolamine-polyethylene glycol,and distearoyl phosphoethanolamine-polyethylene glycol-folic acid; and the medicine is hispidulin and / or epigallocatechin gallate. The invention provides another drug-loaded system as drug-loaded microsphere, which is obtained through entrapment of the medicine by chitosan microsphere, and the medicine is hispidulin. The invention provides an application of hispidulin and / or epigallocatechin gallate in preparation of the medicine for treating lung tumour, and provides the drug-loaded liposome and the drug-loaded microsphere entrapping the hispidulin and / or epigallocatechin gallate. The functional drug-loaded system brings hope for thoroughly treating lung tumour, and has important theoretical significance and clinical meaning.

Accordingly, the present invention provides a method of treating lung neoplasia in a subject in need of treatment, by subjecting the patient to SIRT.

Newly identified proteins as markers for the detection of lung tumors, or as therapeutic targets for their treatment, affinity ligands capable of selectively interacting with the newly identified markers and methods for tumor diagnosis and therapy using such ligands.

The invention belongs to the technical field of biological medicine, and discloses a lung-targeted drug-loaded exosome, application and a medicine for treating lung diseases; the medicine for treating the lung diseases is introduced into the exosome with lung tissue targeting property to obtain the lung-targeted drug-loaded exosome; the exosome with the lung tissue targeting property is derived from colorectal cells; and a lung tumour treatment medicine contains the lung-targeted drug-loaded exosome. Compared with the prior art, the exosome secreted by the colorectal cells can be enriched in the lung without any modification; the exosome derived from the colorectal cells is used; the problem of exosome yield is solved; the application prospect is very good; the exosome from the colorectal cells can be used for loading different medicines or active molecules; and through targeted lung tissue administration, the treatment effect on lung diseases is improved; and toxic and side effects of the medicines are reduced.

The invention discloses a composition for treating lung tumors. The composition is prepared from daurisoline and cisplatin; few medicines are used, and quality control is facilitated; the combined application of the dauricine and the cisplatin has a good killing effect on non-small cell lung cancer no matter at the cellular level or the animal level, can induce tumor cell apoptosis and enhance theanti-tumor effect, which indicates that the dauricine can have a synergistic effect on the cisplatin and improve the clinical drug resistance of the cisplatin; and the composition has important significance for treating lung tumors, especially non-small cell lung cancer, and has huge social value and economic value.

The invention relates to a dietary supplement for preventing lung cancer and a preparation method thereof. The dietary supplement comprises the following ingredients of: by weight, 4-6 parts of pitted dry jujube fresh, 0.9-1.1 parts of tea polyphenol, 0.008-0.016 part of caffeine and 0.01-0.02 part of taurine. The invention has the following advantage: advantages of the complex prescription are performed to achieve outstanding effects of preventing lung cancer. According to mammal experiments, ethylurethanm induced lung cancer in mice is used as an experimental model. These experiments prove that by the application of the dietary supplement in the ethylurethanm intraperitoneally-injected model mice at latency period of lung cancer, the average lung tumor number of mice individuals is minimized by 70%, the volume of individual average lung tumor is reduced by 70%, and incidence rate of lung tumor is decreased by 30%. The supplement provided by the invention has no toxic and side effect within a normal ingestion range. In addition, the preparation technology of the supplement requires low cost and is simple and easy to operate.

Compositions and methods for the diagnosis of lung cancer are disclosed. Such methods are useful to detect early tumors or provide adequate stage / grade information or tumor specificity. Compositions may comprise one or more lung tumor proteins, teins, immunogenic portions thereof, or polynucleotides that encode such portions. Such compositions may be used, for example, to improve lung cancer diagnosis and prognosis and potentially differentiate between NSCLC and SCLC.

The present invention is a method for manufacturing an animal model for researching a pulmonary tumor and a use thereof. A transgenic non-human animal of the present invention is prepared by embryonic gene microinjection and possesses a tissue-specific expression of vascular endothelial growth factor A165 (VEGF-A165) in lung. Through the expression of vascular endothelial growth factor A165, the lung cells in the transgenic non-human animal of the present invention have inflammatory, vascularogenesis and angiogenesis responses or induce lung tumors. Thus, the non-human animal of the present invention can serve as an animal model for analyzing the regulation and the anti-tumor drugs screening of pulmonary adenocarcinoma.